IBD because of the risk of relapse of IBD and an overall increase in disease activity, as well as the general risk of further injury to the gastrointestinal mucosa. 5 Therefore, NSAIDs are used cautiously or are contraindicated in patients with IBD. 6 , 7 Use of COX-2 inhibitors, which may be associated with a lower risk of IBD exacerbations, remains controversial because of potential side effects, such as cardiovascular adverse events. 8 , 9 Moreover, opioid agonists are generally not recommended in patients with IBD because of the risks of ileus, toxic